HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Hib-MenCY-TT vaccine

Also Known As:

Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine; HibMenCY-TT vaccine; MenHibrix

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
Biological Factors: 2472
- Antigens: 143924
  - Synthetic Vaccines: 1073
    - Conjugate Vaccines: 3555
      - Hib-MenCY-TT vaccine: 4

Experts

1.	Briere, Elizabeth C: 1 article (06/2014)
2.	Clark, Thomas A: 1 article (06/2014)
3.	Cohn, Amanda C: 1 article (06/2014)
4.	MacNeil, Jessica R: 1 article (06/2014)
5.	McNamara, Lucy: 1 article (06/2014)
6.	Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC: 1 article (06/2014)
7.	Rubin, Lorry: 1 article (06/2014)
8.	Chhillar, Anil Kumar: 1 article (01/2014)
9.	Dabur, Rajesh: 1 article (01/2014)
10.	Dangi, Mrridula: 1 article (01/2014)

Related Diseases

1.	Meningococcal Infections 06/20/2014 - "MenACWY-D (Menactra, Sanofi Pasteur) is recommended for use in children aged 9 through 23 months who are at increased risk for meningococcal disease, and Hib-MenCY-TT (MenHibrix, GlaxoSmithKline) is recommended for use in children aged 6 weeks through 18 months at increased risk. " 08/01/2013 - "Of four meningococcal vaccines currently licensed in the United States, two conjugate products, (MenACWY-D [Menactra], Sanofi Pasteur; HibMenCY-TT [MenHibrix], GlaxoSmithKline), are recommended for infants and toddlers younger than 2 years who have an increased risk for invasive meningococcal disease. " 01/01/2014 - "Recent approval of new combination based antiviral drugs such as Stribild (combination of four drugs for HIV treatment) and Menhibrix (combination vaccine to prevent meningococcal disease and Haemophilus influenzae type b in children) proves that combination therapy is still the most promising approach to combat the ever evolving pathogens. " 09/01/2012 - "Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD."
2.	Chronic Obstructive Pulmonary Disease (COPD) 09/01/2012 - "Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD."
3.	Human Influenza (Influenza) 09/01/2012 - "Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD."
4.	Bronchial Spasm 09/01/2012 - "Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD."
5.	Breast Neoplasms (Breast Cancer) 09/01/2012 - "Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD."

Related Drugs and Biologics

1.	Meningococcal Vaccines (Meningococcal Vaccine)
2.	Vaccines
3.	MenACWY
4.	Triglycerides (Triacylglycerol)
5.	Powders
6.	Appetite Depressants (Anorectics)
7.	Antiviral Agents (Antivirals)
8.	Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Cobicistat Elvitegravir
9.	lorcaserin
10.	pertuzumab

Related Therapies and Procedures

1.	Therapeutics